Why Nuwellis Stock Is Climbing
Portfolio Pulse from Erica Kollmann
Nuwellis, Inc. (NASDAQ:NUWE) shares are trading higher after the company announced the first pediatric patient treatment with the newly launched Quelimmune therapy. Quelimmune, designed for pediatric patients with acute kidney injury and sepsis, is manufactured by SeaStar Medical Holding Corp (NASDAQ:ICU) and distributed by Nuwellis in U.S. pediatric hospitals. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and a $17 price target.
July 29, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SeaStar Medical Holding Corp, the manufacturer of Quelimmune therapy, may see positive sentiment as Nuwellis successfully treats the first pediatric patient with the therapy.
As the manufacturer of Quelimmune therapy, SeaStar Medical Holding Corp stands to benefit from the successful treatment of the first pediatric patient, potentially leading to increased demand and positive investor sentiment.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Nuwellis shares are up after the first pediatric patient was treated with Quelimmune therapy. Analyst Jonathan Aschoff initiated coverage with a Buy rating and a $17 price target.
The successful treatment of the first pediatric patient with Quelimmune therapy is a significant milestone for Nuwellis, likely boosting investor confidence. Additionally, the Buy rating and $17 price target from analyst Jonathan Aschoff further support a positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100